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Polycyclic aromatic hydrocarbons (PAHs) and
polychlorinated biphenyls (PCBs) are two
classes of environmentally prevalent pollutants.
PAHs are formed through the combustion of
fossil fuels and the burning of organic materi-
als (Dipple 1985). PCBs were ﬁrst produced
industrially in the middle of the last century
for their desirable dielectric properties
(Erickson 2001) and remain in the environ-
ment because of their continued use, because
of their release from waste sites, and because
many congeners are slowly degraded. The
more lipophilic PAHs and PCBs are often
found in the same environmental samples,
such as soils and sediments, and are bio-
transformed in animals by similar pathways
(James 2001).
Of the PAHs, benzo[a]pyrene (BaP) is a
well-studied chemical carcinogen, which is
metabolized by cytochrome P-450 (CYP) to a
variety of products (Dipple 1985). These
include 3-hydroxybenzo[a]pyrene (3-OH-
BaP), a major metabolite of BaP in humans
and animals, which has estrogenic properties
and binds to hemoglobin (Charles et al. 2000;
Sugihara and James 2003). Hydroxylated
PAH metabolites such as 3-OH-BaP are sub-
strates for glucuronidation and sulfonation,
catalyzed by one or more of the UDP-glu-
curonosyltransferases and 3´-phosphoadeno-
sine 5´-phosphosulfate (PAPS)-dependent
sulfotransferases (SULTs), respectively (James
et al. 2001). Sulfonation is considered a
detoxiﬁcation pathway for 3-OH-BaP.
PCBs have several metabolites of toxico-
logic importance, including the polychloro-
biphenylols (OH-PCBs), which are formed
in vivo from CYP-dependent mono-oxygena-
tion of PCBs (James 2001). Although they
are slightly more hydrophilic than are the
parent PCBs, several OH-PCBs are elimi-
nated slowly (Klasson-Wehler et al. 1993).
People who are highly exposed to PCBs
through the diet typically have OH-PCBs in
their blood, some bound to plasma proteins
(Guvenius et al. 2003; Sandau et al. 2000).
Several OH-PCB congeners interact with
components of the endocrine system, poten-
tially interfering with thyroid hormone and
estrogen function (Lans et al. 1993; Safe
1994; Schuur et al. 1998). Although the
OH-PCBs have low afﬁnities for both α and
β estrogen receptors, some OH-PCBs are
strikingly potent inhibitors of human estro-
gen sulfotransferase (SULT1E1), with sub-
nanomolar concentrations that produced
50% inhibition (IC50) (Kester et al. 2000).
This suggests that OH-PCBs may be indi-
rectly estrogenic by increasing estradiol
bioavailability in target tissues. As well as pos-
sibly causing toxicity by inhibiting the sulfo-
nation of hormones, several OH-PCBs
inhibited the sulfonation and glucuronidation
of the PAH metabolite 3-OH-BaP in channel
catﬁsh intestine (van den Hurk et al. 2002).
Sulfonation is an important phase II con-
jugation pathway for the detoxification of
xenobiotics as well as the modulation of
endogenous compounds such as thyroid hor-
mones, steroids, and neurotransmitters
(Coughtrie et al. 1998). One or more mem-
bers of a superfamily of cytosolic SULT
enzymes catalyze these reactions (Blanchard
et al. 2004). SULT1A1, SULT1B1, and
SULT1E1 are the major phenol sulfotrans-
ferases expressed in human liver, with
SULT1A1 (also known as ST1A3) found at
the highest concentration (Honma et al.
2002). SULT1A3 is expressed in the gut but
is present in very low concentrations in adult
human liver (Richard et al. 2001). Genetic
polymorphisms are known for SULT1A: a
G638→A transition leading to an Arg213→His
exchange in the protein was observed with a
frequency of 33.2% in Caucasian subjects,
8% in Chinese, and 29.4% in African Ameri-
cans (Carlini et al. 2001). SULT1A1*His
(SULT1A1*2) was a less thermostable protein
than SULT1A1*Arg (SULT1A1*1), and some
authors have reported that the SULT1A1*2
variant is less catalytically active (Ozawa et al.
1998; Raftogianis et al. 1997).
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Sulfonation is a major phase II biotransformation reaction. In this study, we found that several
polychlorobiphenylols (OH-PCBs) inhibited the sulfonation of 3-hydroxybenzo[a]pyrene
(3-OH-BaP) by human liver cytosol and some cDNA-expressed sulfotransferases. At concentra-
tions > 0.15 µM, 3-OH-BaP inhibited its own sulfonation in cytosol fractions that were geno-
typed for SULT1A1 variants, as well as with expressed SULT1A1*1, SULT1A1*2, and SULT1E1,
but not with SULT1A3 or SULT1B1. The inhibition ﬁt a two-substrate kinetic model. We exam-
ined the effects of OH-PCBs on the sulfonation of 0.1 or 1.0 µM 3-OH-BaP, noninhibitory and
inhibitory substrate concentrations, respectively. At the lower 3-OH-BaP concentration,
OH-PCBs with a 3-chloro-4-hydroxy substitution pattern were more potent inhibitors of cyto-
solic sulfotransferase activity [with concentrations that produced 50% inhibition (IC50) between
0.33 and 1.1 µM] than were OH-PCBs with a 3,5-dichloro-4-hydroxy substitution pattern, which
had IC50 values from 1.3 to 6.7 µM. We found similar results with expressed SULT1A1*1 and
SULT1A1*2. The OH-PCBs were considerably less potent inhibitors when assay tubes contained
1.0 µM 3-OH-BaP. The inhibition mechanism was noncompetitive, and our results suggested
that the OH-PCBs competed with 3-OH-BaP at an inhibitory site on the enzyme. The OH-PCBs
tested inhibited sulfonation of 3-OH-BaP by SULT1E1, but the order of inhibitory potency was
different than for SULT1A1. SULT1E1 inhibitory potency correlated with the dihedral angle of
the OH-PCBs. The OH-PCBs tested were generally poor inhibitors of SULT1A3- and
SULT1B1-dependent activity with 3-OH-BaP. These findings demonstrate an interaction
between potentially toxic hydroxylated metabolites of PCBs and polycyclic aromatic hydro-
carbons, which could result in reduced clearance by sulfonation. Key words: 3-hydroxy-
benzo[a]pyrene, human liver cytosol, inhibition of sulfonation, polychlorobiphenylols,
SULT1A1*1, SULT1A1*2, SULT1E1. Environ Health Perspect 113:680–687 (2005).
doi:10.1289/ehp.7837 available via http://dx.doi.org/ [Online 24 February 2005]Because people are frequently coexposed
to PAHs and PCBs, we wished to determine
if OH-PCBs would inhibit 3-OH-BaP sulfo-
nation in human liver (HL) cytosol and,
if so, whether the inhibition was isozyme
selective. We used cDNA-expressed human
SULT1A1*1, -1A1*2, -1A3, -1B1, and 1E1
isozymes, which we expected would use
3-OH-BaP as substrate. We genotyped the
HL cytosol fractions used in this study, with
respect to the common SULT1A1 polymor-
phic variants, to examine the possibility that
OH-PCBs would affect their activity differ-
ently. These studies were conducted with a
series of predominantly para-OH-PCBs.
Materials and Methods
Materials. The structures of the OH-PCBs
used in this study are shown in Figure 1. In
naming these OH-PCBs, we followed the
recommendation of Maervoet et al. (2004) to
name them as metabolites of PCBs, referring
back to the Ballschmiter and Zell numbering
system for PCBs (Ballschmiter and Zell 1980).
The 6´-OH-CB35 (A1), 4´-OH-CB35 (B1),
4´-OH-CB36 (B2), 4´-OH-CB79 (C1), and
4-OH-CB36 (C2) were synthesized by Suzuki
coupling as described previously (Bauer et al.
1995; Lehmler and Robertson 2001). We veri-
ﬁed the structures of each of these OH-PCBs
by 1H and 13C-nuclear magnetic resonance
spectroscopy, Fourier transform infrared spec-
troscopy, and gas chromatography–mass spec-
trometry (GC-MS). We found that each
OH-PCB was > 99% pure by GC-MS analysis
(Mass Spectrometry Facility, University of
Kentucky, Lexington, KY), combustion analy-
sis (Atlantic Microlab, Atlanta, GA), and thin-
layer chromatography. The 4´-OH-CB69
(B3), 4´-OH-CB106 (B4), 4´-OH-CB112
(B5), 4´-OH-CB121 (C3), 4´-OH-CB159
(C4), 4´-OH-CB165 (C5), and 4´-OH-CB72
(C6) were purchased from AccuStandard
(New Haven, CT). S.S. Singer (University of
Dayton, Dayton, OH) supplied the PAPS. We
purchased 35S-PAPS, 3.05 µCi/nmol (99.1%
pure), from PerkinElmer Life Science (Boston,
MA). Benzo[a]pyrene-3-sulfate (BaP-3-SO4)
and 3-hydroxybenzo[a]pyrene (3-OH-BaP)
were purchased from the NCI Chemical
Carcinogen Reference Standard Repository
(Midwest Research Institute, Kansas City,
MO). We obtained HaeII from Fisher
Scientiﬁc (Atlanta, GA) and Taq DNA polym-
erase, along with other polymerase chain
reaction (PCR) reagents, from Promega
(Madison, WI). Integrated DNA Technologies
(Coralville, IA) supplied primers for use in
genotyping. We purchased the highest avail-
able grade of other reagents from Fisher
Scientiﬁc (Atlanta, GA) and Sigma Chemical
Company (St. Louis, MO).
Physicochemical properties of the
OH-PCBs. We calculated the structural
characteristics of dihedral angle, molecular vol-
ume, molecular surface area, pKa, log P, and
log D at pH 7.0 with MM2* using GB/SA
water solvent continuum as implemented by
MacroModel 5.0 (Schrödinger, Portland, OR)
and described previously by Tampal et al.
(2002).
Cytosolic preparations. F.P. Guengerich
(Vanderbilt University) kindly donated the
samples of human liver, which were procured
from organ donors (Guengerich 1995). We
prepared liver cytosolic fractions from four
livers by standard methods and stored
aliquots at −80°C until use (Wang et al.
2004). We used three or four of these cytosol
fractions in each experiment.
SULT1A1 genotype determination. We
used a genomic DNA isolation kit (EASY-
DNA; InVitrogen, Carlsbad, CA) to extract
genomic DNA from samples of the individual
human livers used in this study. We used a
published method to detect the SULT1A1
polymorphism status of each liver (Nowell et al.
2000; Ozawa et al. 1998). Amplified DNA
fragments were digested with HaeII, and the
fragments were resolved on 2% (weight/vol-
ume) agarose gels. Fragments from individuals
homozygous for SULT1A1*1 exhibited two
bands, visualized by ultraviolet transillumina-
tion, whereas DNA fragments from individuals
homozygous for SULT1A1*2 were not cleaved
by this enzyme and exhibited one band.
Expression and partial purification of
SULT isozymes. The expression of human
SULT1A1*1, SULT1A3, SULT1B1, and
SULT1E1 in Escherichia coli has been described
previously (Dajani et al. 1998; Wang et al.
1998). We grew E. coli cells containing the
respective sulfotransferase genes as described
previously (Falany et al. 1990, 1994), and pre-
pared 100,000g supernatant fractions for use in
inhibition studies and for partial puriﬁcation of
the SULT enzymes. We purchased expressed
SULT1A1*2 cytosolic extract from PanVera
(Madison, WI) and used it as supplied.
The 100,000g supernatant fractions of
SULT1A1*1, SULT1A3, SULT1B1, and
SULT1E1 were partially puriﬁed by chromato-
graphic methods (Falany et al. 1990, 1994).
After the last step, a 3'-phosphoadenosine
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Figure 1. Structures of the hydroxylated PCBs used in this study. Type A, hydroxy without a ﬂanking chlorine
atom; type B, para-hydroxy with one ﬂanking chlorine atom; type C, para-hydroxy with two ﬂanking chlorine
atoms.5'-phosphate (PAP)-agarose affinity column,
we dialyzed the fractions eluted with PAP with
three changes of buffer to remove PAP before
the assay of SULT activity with 3-OH-BaP as
substrate. We analyzed active fractions by
SDS-PAGE (Laemmli 1970) to assess the
purity of each SULT enzyme. We stained the
gels with Coomassie R-250 reagent and deter-
mined the percentage of protein present as
each respective SULT enzyme by scanning
densitometry.
Kinetic analysis of 3-OH-BaP sulfonation.
We determined SULT activity with 3-OH-
BaP as substrate by a fluorimetric assay of
BaP-3-SO4 product formation, as described
previously (Wang et al. 2004). We ensured
that the formation of BaP-3-SO4 was linear
for time and protein and did not exceed 10%
of the added 3-OH-BaP with each of the
enzyme sources used. Duplicate tubes were
prepared for each incubation condition. We
examined the kinetics of sulfonation in three
liver cytosol fractions by systematically varying
the concentration of 3-OH-BaP or PAPS.
When the variable substrate was 3-OH-BaP,
we used 12 concentrations in the range from
0.035 to 2.00 µM, and the concentration of
PAPS was kept constant at 10 µM. When we
varied PAPS, we used 7 concentrations from
0.157 to 10.0 µM and kept the concentration
of 3-OH-BaP constant at 0.100 µM.
We determined the kinetic parameters for
3-OH-BaP sulfonation by partially purified
preparations of the cDNA-expressed SULT
isozymes under incubation conditions similar
to those used for liver cytosol. For SULT1A1*1
and -1A1*2, we used seven substrate concen-
trations in the range from 5 to 100 nM; for
SULT1E1 we used six 3-OH-BaP concentra-
tions from 15.6 to 1,000 nM; and for
SULT1A3 and 1B1 we used seven concentra-
tions of 3-OH-BaP from 0.25 to 5.0 µM.
Inhibition of SULT activity by OH-PCBs.
To assess inhibition of 3-OH-BaP SULT
activity, we prepared stock solutions of
OH-PCBs in dimethyl sulfoxide (DMSO) and
added aliquots to incubation mixtures such that
the ﬁnal concentration of OH-PCB was in the
range of 0.01–200 µM and the DMSO con-
centration did not exceed 0.5% (vol/vol). For
each OH-PCB, we examined the concentra-
tion dependence of inhibition with three liver
cytosol fractions, as well as with cytosol frac-
tions from the E. coli expressing SULT1A1*1,
SULT1A3, SULT1B1, and SULT1E1, and
the purchased Sf-9 cytosol fraction (PanVera,
Madison, WI) containing SULT1A1*2. For
studies with HL cytosol, SULT1A1*1, and
SULT1E1, we examined two concentrations
of 3-OH-BaP, 0.1 µM and 1.0 µM. For stud-
ies with SULT1A1*2, we examined only
0.1 µM 3-OH-BaP, a concentration that did
not elicit substrate inhibition. For studies with
SULT1B1, we used only 1.0 µM 3-OH-BaP
because this enzyme had very low activity at
0.1 µM 3-OH-BaP and did not exhibit sub-
strate inhibition. Examination of the effect of
50 µM concentrations of several OH-PCBs on
the activity of SULT1A3, measured with
1.0 µM 3-OH-BaP, revealed little inhibition,
so no further concentrations were studied.
Kinetics of inhibition. To study the type
of inhibition produced by OH-PCBs, we used
4´-OH-CB112 (B5) as a model inhibitor. We
prepared four sets of assay tubes containing
HL cytosol and varying amounts of 3-OH-
BaP from 35 to 150 nM: one set (control)
contained no 4´-OH-CB112; the other sets
contained 0.25 µM, 0.5 µM, or 1.0 µM
4´-OH-CB112.
Data analysis. We calculated the enzyme
kinetic parameters from studies with variable
concentrations of 3-OH-BaP using nonlinear
regression analysis and GraphPad 4.0 software
(GraphPad Software, San Diego, CA). We
selected the built-in Michaelis-Menten equa-
tion for most analyses. Where we found evi-
dence of 3-OH-BaP substrate inhibition, we
fit the data into an equation derived from a
two-substrate model (Zhang et al. 1998): 
V = V1[1 + (V2S/V1Ki)]
÷(1 + Km/S + S/Ki). 
This equation denoted the constant for binding
of the ﬁrst substrate (S) molecule as Km and the
second substrate molecule as Ki. V1 is the maxi-
mum rate for the noninhibitory substrate con-
centration range, and V2 is the minimum rate
in the inhibitory substrate concentration range
We calculated the effects of OH-PCBs on
3-OH-BaP SULT activity as percentage inhi-
bition compared with the controls without an
inhibitor. We obtained IC50 values by ﬁtting
log OH-PCB concentration and percent con-
trol activity to a sigmoidal curve. We examined
the relationships between IC50 and physico-
chemical properties of the OH-PCBs by linear
correlation analysis. We calculated the inhi-
bitory constant (Ki) from the kinetic studies
with 4´-OH-CB112 by means of Dixon plots
and plots of Km/Vmax against inhibitor concen-
tration (Cornish-Bowden 1995).
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Figure 2. Detection of SULT1A1*1/*2 alleles by
restriction fragment length polymorphism analysis.
Lane M, marker; lane 1, SULT1A1*2/*2 homozygous;
lane 2, SULT1A1*1/*2 heterozygous; lane 3,
SULT1A1*1/*1 homozygous. Speciﬁc PCR products
were generated and digested with HaeII as
described in “Materials and Methods.”
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Figure 3. Rates of sulfonation of 3-OH-BaP (0.1 µM) in the presence of varying concentration of PAPS
(0.125–10 µM) in HL cytosol (A) and cytosol of SULT1A1*2 (B). Data in (A) are given as the mean ± SD of
three experiments.
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Figure 4. Partial substrate inhibition by 3-OH-BaP in HL cytosol from three individuals (A) and SULT1A1*2 (B).Results
SULT1A1 genotype of the liver donors. We
found that the HL cytosols used were from
individuals with different SULT1A1 genotypes,
as determined by PCR amplification of the
region of the SULT1A gene ﬂanking the poly-
morphic base pair. The G to A mutation in
SULT1A1 removed the restriction site for the
endonuclease HaeII. As shown in Figure 2, an
individual homozygous for the SULT1A1*2
allele did not have the HaeII restriction site, and
the PCR product was not cleaved (lane 1). The
PCR product from the individual homozygous
for SULT1A1*1 showed complete cleavage by
HaeII, generating two fragments of approxi-
mately 100 and 181 bp (lane 3). Enzymatic
digestion of the PCR product from the het-
erozygote (SULT1A1*1/*2) generated one
band of 281 bp and the two fragments of
100 and 181 bp (lane 2). Thus, the individual
liver designated HL 1 was homozygous for
the SULT1A1*1 allele, HL 2 was heterozy-
gous, and HL 3 was homozygous for the
SULT1A1*2 allele.
Sulfonation of 3-OH-BaP by HL cytosol
and expressed human SULT isoforms. Initial
studies of the sulfonation of 3-OH-BaP by
HL cytosol revealed that concentrations of
3-OH-BaP > 0.15 µM resulted in a decrease
in activity. To ﬁnd a saturating concentration
of PAPS, we conducted incubations in the
presence of 0.1 µM 3-OH-BaP and varying
concentrations of PAPS. The data fit the
Michaelis-Menten equation, with an apparent
Km of 0.56 ± 0.09 µM and a Vmax of 48 ±
2 pmol/min/mg protein (mean ± SD; n = 3).
The dependence of activity upon PAPS con-
centration in expressed human SULT1A1*2,
in the presence of 0.1 µM 3-OH-BaP, also
followed Michaelis-Menten kinetics. The
apparent Km was 0.32 µM, and Vmax was
684 pmol/min/mg protein. As shown in
Figure 3, cytosol and the expressed enzyme
were saturated by a PAPS concentration of
10 µM, and we used this concentration in
subsequent studies.
We conducted detailed studies of the
effect of a range of 3-OH-BaP concentrations
up to 2 µM on reaction rates with HL cytosol
and expressed human SULT1A1*2. We
obtained preliminary estimates of the kinetic
constants Km and V1 by ﬁtting the initial rates
of sulfonation at concentrations < 0.15 µM
3-OH-BaP to the Michaelis-Menten equa-
tion. We then obtained the values of Ki and
V2 through constraining Km using the equa-
tion of Zhang et al. (1998). We also analyzed
data by constraining V1, but a better fit was
found when constraining Km. Figure 4A shows
how the data ﬁt this equation for three individ-
ual HL cytosols. Kinetic studies with expressed
SULT1A1*2 revealed substrate inhibition with
the single enzyme (Figure 4B). Table 1 shows
values for Km, Ki, V1, and V2 for each HL
cytosol and the expressed SULT1A1*2. The
expressed enzyme showed a lower value for Km
(0.022 µM) and Ki (0.16 µM) than did any of
the HL cytosols.
Table 2 shows the results of kinetic studies
with the other expressed human enzymes. The
values shown in Table 2 are from substrate con-
centration ranges in which the data fit the
Michaelis-Menten equation. SULT1A1*1 and
SULT1E1 showed substrate inhibition at con-
centrations of 3-OH-BaP > 0.15 µM, but
detailed kinetic analyses at inhibitory concen-
trations was not conducted with these expressed
enzymes. We found that SULT1A1*1 had an
apparent Km (0.018 µM) similar to that found
with SULT1A1*2 (0.022 µM). SULT1E1 also
had high afﬁnity for 3-OH-BaP, with an appar-
ent Km of 0.05 µM. SULT1A3 and SULT1B1
did not exhibit substrate inhibition over a con-
centration range up to 5 µM and showed much
higher apparent Km values for 3-OH-BaP.
These expressed enzyme preparations were par-
tially purified, and SDS-PAGE showed they
contained different percentages of the respective
SULT enzymes (Table 2). The values shown
for Vmax were corrected for the percentage of
each respective SULT isoform in the partially
puriﬁed enzyme preparation.
Inhibition of 3-OH-BaP sulfonation by
OH-PCBs with HL cytosol. The 4-OH-PCBs
with one (B group) or two (C group) ﬂanking
chlorine substituents inhibited HL cytosolic
3-OH-BaP sulfotransferase activity in a con-
centration-dependent manner. Figure 5A
shows inhibition curves from selected
OH-PCBs in the presence of 0.1 µM 3-OH-
BaP, and Figure 5B shows the same com-
pounds studied with 1.0 µM 3-OH-BaP.
Table 3 presents the IC50 values of 3-OH-
BaP sulfotransferase activity with all the tested
compounds, each at two concentrations of
3-OH-BaP. Compounds B1–B5 with the
3-chloro-4-hydroxy substitution pattern were
potent inhibitors, with IC50 values ranging
from 0.33 to 1.08 µM, when activity was mea-
sured with 0.1 µM 3-OH-BaP. The OH-PCBs
with two chlorine atoms ﬂanking the hydroxy
group (C1–C6) were less potent inhibitors
under these conditions (IC50, 1.31–6.71 µM;
Table 3). The single 6-OH-PCB studied, A1,
was a very weak inhibitor, with an IC50 of
> 100 µM (Figure 5). When activity was
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Figure 5. Inhibition of 3-OH-BaP sulfotransferase in HL cytosol by OH-PCBs. (A) 0.1 µM 3-OH-BaP.
(B) 1.0 µM 3-OH-BaP. 3-OH-BaP sulfotransferase activity is given as percentage of control. Data given are
the mean ± SD of three experiments. Structures of the tested OH-PCBs are shown in Figure 1.
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Table 1. Kinetic parameters for 3-OH-BaP sulfonation by human livers and SULT1A1*2.
V1 V2
Km (µM) Ki (µM) (pmol/min/mg protein) (pmol/min/mg protein) R2
HL 1 cytosol 0.048 0.915 121 2 0.95
HL 2 cytosol 0.051 0.534 93.0 38.50 0.956
HL 3 cytosol 0.048 0.460 94.4 31.0 0.958
Mean ± SD 0.049 ± 0.01 0.636 ± 0.244 102 ± 15.8 28.3 ± 19.3
SULT1A1*2 0.022 0.160 4,400 290 0.953
Kinetic analysis was performed using a two-substrate model as described in “Materials and Methods.” HL 1 cytosol was
homozygous for SULT1A1*1, HL 2 cytosol was heterozygous as SULT1A1*1/*2, and HL 3 cytosol was homozygous for
SULT1A1*2.
Table 2. Apparent kinetic constants for cDNA-expressed sulfotransferase with 3-OH-BaP as substrate.
SULT Km (µM) Vmax (nmol/min/mg protein) Vmax/Km (mL/min/mg protein)
SULT1A1*1 0.018 6.89 383
SULT1A3 2.90 333.3 115
SULT1B1 2.00 9.70 4.9
SULT1E1 0.05 8.35 167
Partially puriﬁed SULT isoforms were used for these studies. Vmax was calculated from the mg/mL of the partially puriﬁed
preparation and corrected by the percentage of protein estimated to be SULT, from SDS-PAGE: 44.0% for SULT1A1*1,
39.0% for SULT1A3, 80.3% for SULT1B1, and 65.0% for SULT1E1.measured with 1 µM 3-OH-BaP, a concentra-
tion at which substrate inhibition occurred, the
measured IC50 values showed lower inhibitory
potencies for all OH-PCBs, but especially so for
the C group compounds, whose IC50 values
ranged from 3 to 58.7 µM (Table 3).
Inhibition of 3-OH-BaP sulfonation by
OH-PCBs with cDNA-expressed SULTs. For
SULT1A1*1, Figure 6A shows inhibition
curves with selected OH-PCBs using 0.1 µM
3-OH-BaP, whereas Figure 6B shows results
with a substrate concentration of 1.0 µM
3-OH-BaP. We found that 6´-OH-CB35 (A1)
was a poor inhibitor of 3-OH-BaP sulfonation
under both conditions of substrate concentra-
tion. When using 0.1 µM 3-OH-BaP, type B
compounds (B1–B5) showed IC50 values rang-
ing from 0.77 to 1.31 µM, whereas type C
compounds (C1–C6) exhibited IC50 from
2.16 to 6.65 µM (Table 3). When using
1.0 µM 3-OH-BaP, the inhibitory potencies of
the OH-PCBs were dramatically reduced. The
IC50 values for type B OH-PCBs were reduced
to 10.3–67.5 µM, and for type C OH-PCBs
were 33.8 to > 100 µM (Table 3).
For SULT1A1*2, the IC50 of 6´-OH-
CB35 (A1) was > 100 µM, as shown in
Table 3. At 0.1 µM 3-OH-BaP, the IC50
ranged from 0.54 to 1.48 µM for type B
(B1–B5) compounds and from 1.67 to
6.52 µM for type C compounds (C1–C6).
When using 1.0 µM 3-OH-BaP, the OH-PCB
IC50 was approximately 5 µM for type B
(B1–B5) compounds and 50 µM for type C
(C1–C6) compounds (data not shown).
As shown in Figure 7, expressed SULT1A3
was not inhibited or was weakly inhibited by
OH-PCBs when 3-OH-BaP was used at the
noninhibitory concentration of 1.0 µM.
Addition of 50 µM concentrations of com-
pounds 6´-OH-CB35 (A1), 4´-OH-CB69
(B3), 4´-OH-CB106 (B4), 4´-OH-CB112
(B5), 4´-OH-CB121 (C3), 4´-OH-CB165
(C5), and 4´-OH-CB72 (C6) did not inhibit
the sulfonation of 3-OH-BaP. Compounds 4´-
OH-CB35 (B1), 4´-OH-CB36 (B2), 4´-OH-
CB79 (C1), and 4´-OH-CB159 (C4) showed
2–20% inhibition at 50 µM, and 4-OH-CB36
(C2) produced 43% inhibition. Because
SULT1A3 activity was poorly inhibited by
50 µM concentrations, we did not examine a
range of concentrations of OH-PCBs. 
Expressed SULT1B1 showed a quite dif-
ferent inhibitory interaction with OH-PCBs,
compared with SULT1A1*1, SULT1A1*2,
SULT1A3, and SULT1E1, in that 6´-OH-
CB35 (A1) was a quite potent inhibitor (IC50,
4.72 µM) of 3-OH-BaP sulfonation (Table 3).
Compounds B1 (4´-OH-CB35) and B4
(4´-OH-CB106) showed IC50 values of 16.76
and 17.45 µM, respectively. The other type B
and type C OH-PCBs were weak inhibitors. 
For SULT1E1, compound A1 (6´-OH-
CB35) was a poor inhibitor of 3-OH-BaP
sulfonation at either of the substrate concentra-
tions studied (Table 3). When using 0.1 µM
3-OH-BaP, OH-PCBs with no or one ortho-
substituted chlorine (B1, B2, B4, C1, C2, C4,
and C6) were potent inhibitors of 3-OH-BaP
sulfonation, with IC50 values between 0.24
and 1.3 µM (Table 3). The OH-PCBs with
two ortho-substituted chlorine atoms (B3, B5,
C3, and C5) were less potent inhibitors, with
IC50 values of 4.87–7.98 µM (Table 3). When
we used 1.0 µM 3-OH-BaP as substrate, there
was a 3- to 5-fold reduction in inhibitory
potency, and the order of potency remained as
it was with 0.1 µM 3-OH-BaP.
Structure–activity relationships. For HL
cytosol, expressed SULT1A1*1, SULT1A1*2,
and SULT1E1, we investigated the relation-
ship between inhibitory potency, measured at
0.1 µM 3-OH-BaP, and each of several
physicochemical properties of the 4-OH-
PCBs. For HL cytosol, SULT1A1*1, and
SULT1A1*2, we found no signiﬁcant correla-
tion between dihedral angle, molecular surface
area, molecular surface volume, log P, log D
at pH 7.0, or pKa. The IC50 values with
SULT1E1 showed a significant (p < 0.001)
linear correlation with dihedral angle, as
shown in Figure 8. No other signiﬁcant corre-
lations were found.
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Figure 6. Inhibition of 3-OH-BaP sulfotransferase in SULT1A1*1 by OH-PCBs. (A) 0.1 µM 3-OH-BaP.
(B) 1.0 µM 3-OH-BaP. 3-OH-BaP sulfotransferase activity is given as percentage of control. Data given are
the mean ± SD of three experiments. Structures of the tested OH-PCBs tested are shown in Figure 1.
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Figure 7. Inhibition of 3-OH-BaP sulfotransferase
activity with SULT1A3 by OH-PCBs shown in
Figure 1, each at 50 µM.
Table 3. In vitro inhibition of 3-OH-BaP sulfotransferase activity by the tested OH-PCBs using HL cytosol and cDNA-expressed sulfotransferases at 0.1 and 1.0 µM
substrate concentration.a
IC50 (µM)
Compound Log D at Dihedral 0.1 µM 3-OH-BaP 1.0 µM 3-OH-BaP
no. Compound pH 7.0 angle (º) HL cytosol SULT1A1*1 SULT1A1*2 SULT1E1 HL cytosol SULT1A1*1 SULT1B1 SULT1E1
A1 6´-OH-CB35 4.7 50 > 100 > 100 > 100 ~100 > 100 > 100 4.72 > 100
B1 4´-OH-CB35 4.7 38 0.33 ± 0.02 0.77 0.55 0.24 0.96 ± 0.30 25.2 16.8 1.02
B2 4´-OH-CB36 4.8 38 0.67 ± 0.12 1.31 0.94 0.45 1.05 ± 0.39 28.0 37.0 1.89
B3 4´-OH-CB69 5.1 72 0.91 ± 0.09 1.16 1.31 4.87 1.50 ± 0.32 67.5 > 100 30.8
B4 4´-OH-CB106 5.2 60 0.37 ± 0.04 1.07 1.06 1.18 2.61 ± 0.67 10.3 17.4 6.97
B5 4´-OH-CB112 5.2 78 1.08 ± 0.12 1.17 1.48 5.35 4.22 ± 1.03 42.5 86.5 23.2
C1 4´-OH-CB79 4.5 38 6.71 ± 0.91 6.65 4.57 0.50 58.7 ± 13.9 59.8 39.9 1.32
C2 4-OH-CB36 4.2 38 2.30 ± 0.45 3.09 3.05 0.41 35.9 ± 1.47 > 100 47.5 1.65
C3 4´-OH-CB121 4.7 72 3.95 ± 0.23 8.15 6.52 7.98 44.6 ± 6.42 99.5 > 100 16.7
C4 4´-OH-CB159 4.7 78 1.31 ± 0.14 2.16 1.67 1.30 38.4 ± 15.2 34.1 > 100 3.55
C5 4´-OH-CB165 4.6 78 2.87 ± 0.09 2.58 2.59 6.96 47.3 ± 10.2 54.8 > 100 21.4
C6 4´-OH-CB72 4.5 57 1.72 ± 0.21 2.21 2.03 0.57 3.05 ± 0.41 33.8 > 100 2.28
aValues for HL cytosol are the means ± SDs of three livers, tested in duplicate; results for expressed SULT enzymes are the means of duplicate determinations.Kinetics of 3-OH-BaP sulfotransferase
inhibition by 4´-OH-CB112. We investigated
the type of inhibition of 3-OH-BaP sulfo-
nation using HL cytosol. Figure 9A shows that
4´-OH-CB112 (B5) reduced sulfotransferase
activities at all the tested 3-OH-BaP concentra-
tions in a concentration-dependent manner.
The kinetic constants showed a steady reduc-
tion in Vmax with increasing concentration of
4´-OH-CB112, but little change in Km, indi-
cating a noncompetitive type of inhibition
(Table 4). Figure 9B shows a plot of Km/Vmax
versus the concentration of 4´-OH-CB112,
which indicated a Ki value for 4´-OH-CB112
of 0.52 ± 0.14 µM.
Discussion
The major human metabolite of BaP, 3-OH-
BaP, was very readily sulfonated in HL cytosol,
especially at concentrations < 0.15 µM. We
observed substrate inhibition in HL cytosol
and with SULT1A1 and SULT1E1, but not
with SULT1A3 or SULT1B1. We studied the
kinetics of substrate inhibition in liver cytosol
and SULT1A1*2 and found that they fit a
two-substrate model proposed for the sulfona-
tion of estradiol by SULT1E1. This model
suggested that SULT1E1 could bind two
molecules of estradiol per molecule of enzyme,
one at a preferred site for sulfonation and the
other at an allosteric site associated with sub-
strate inhibition (Zhang et al. 1998). Our
results suggest a similar scenario for the interac-
tion of 3-OH-BaP with SULT in HL cytosol
and SULT1A1. The Km values for each of the
three tested HL cytosol fractions (48–51 nM),
SULT1A1*2 (22 nM), and SULT1A1*1
(18 nM) were low, indicating that 3-OH-BaP
has a very high afﬁnity for human SULT1A1.
The Ki values were about 10-fold higher. The
3-OH-BaP was not, however, specific for
SULT1A1 but was a substrate for the other
human phenol sulfotransferases studied. In
particular SULT1E1 showed a high afﬁnity for
3-OH-BaP, with a Km of 50 nM. A related
compound, 1-hydroxypyrene, also had a very
low Km with SULT1A1 (8 nM) and SULT1E1
(21 nM) but a higher Km with SULT1A3
(0.8 µM) (Ma et al. 2003). When we calcu-
lated 3-OH-BaP clearance values (Vmax/Km) for
the four partially puriﬁed SULT isoforms, the
highest value was found for SULT1A1*1
(Table 2). Thus, 3-OH-BaP was a selective but
not specific substrate for SULT1A1. Other
investigators showed that the SULT1B1 pro-
tein content in liver cytosol was about one-
fourth that of SULT1A1 (Honma et al. 2002).
The present study showed that expressed
SULT1B1 had a 40-fold higher Km value
(2.0 µM) than found in HL cytosol (0.05 µM),
so it is not likely to contribute much to HL
cytosolic sulfonation of 3-OH-BaP at 0.1 µM
substrate concentration (Table 2). Although
SULT1A3 had activity with 3-OH-BaP, it is
expressed at very low levels in the adult liver
(Richard et al. 2001) and is unlikely to con-
tribute much to 3-OH-BaP sulfonation in
human liver. Because Km values for 3-OH-BaP
in HL cytosol were similar to those of puriﬁed
SULT1A1 and SULT1E1, and others have
shown that SULT1A1 is expressed in liver at
approximately 14-fold higher concentrations
than SULT1E1 (Honma et al. 2002), we con-
clude that the observed activity with 3-OH-
BaP in HL cytosol is catalyzed largely by
SULT1A1. Differing structural features for
inhibition of SULT1A1 and SULT1E1 by
OH-PCBs further support our conclusion that,
in HL cytosol, activity with 3-OH-BaP is due
primarily to SULT1A1. By chance, the three
HL cytosol fractions we used in these studies
were from individuals with different SULT1A1
genotypes. One was SULT1A1*1 homozygous,
a second was heterozygous for SULT1A1*1/*2,
and the third was SULT1A1*2 homozygous.
Kinetic analysis showed little difference among
the three cytosol fractions for V1, which was
121 pmol/min/mg for the homozygous
SULT1A1*1 liver and 94 pmol/min/mg pro-
tein for the SULT1A1*2 liver (Table 1); how-
ever, the small size of our sample precludes a
more detailed analysis of genotype effects on
3-OH-BaP sulfonation activities.
In previous studies, we showed that
OH-PCBs inhibited 3-OH-BaP sulfonation
in catfish intestinal cytosol (van den Hurk
et al. 2002) and that a compound structurally
related to OH-PCBs, 2,4,4´-trichloro-2´-
hydroxydiphenyl ether (triclosan), inhibited
sulfonation and glucuronidation of 3-OH-
BaP and other substrates in HL cytosol and
with SULT1A1, SULT1B1, and SULT1E1
(Wang et al. 2004). Here we demonstrated
that a set of 4-OH-PCBs inhibited SULT
activity with 3-OH-BaP, the major metabolite
of another pollutant chemical, BaP, in HL
cytosol as well as with cDNA-expressed
SULTs. In HL cytosol, all the 4-OH-PCBs
examined inhibited the sulfonation of
3-OH-BaP. Under incubation conditions in
which the 3-OH-BaP substrate did not cause
substrate inhibition (0.1 µM 3-OH-BaP),
compounds with one chlorine atom adjacent
to the OH group (B1–B5) were more potent
inhibitors of sulfonation than were com-
pounds in type C, with chlorine atoms ﬂank-
ing the OH group on each side. We observed
very similar results for potency of inhibition
and order of inhibitory potency with all three
liver cytosol fractions and the two allelic vari-
ants of expressed SULT1A1. When incubated
with 1.0 µM 3-OH-BaP, a concentration that
produced substrate inhibition in liver cytosol
and with both SULT1A1 variants, the
OH-PCBs were considerably less potent
inhibitors in cytosol and even more so with the
expressed SULT1A1*1 and SULT1A1*2
enzymes (Table 3 and data not shown). The
effect of substrate concentration on the
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Figure 8. Correlation of IC50 values (µM) for type B
and type C 4-OH-PCBs with dihedral angles in the
presence of SULT1E1. The regression line was sig-
nificantly different from zero (p < 0.001), and the
goodness of ﬁt (r2) was 0.73 for the positive corre-
lation of SULT1E1 IC50 values with a dihedral angle.
8
6
4
2
0
30
I
C
5
0
 
(
µ
M
)
40 50 60 70 80
Dihedral angle
60
50
40
30
20
10
0
0.05
B A
V
 
(
p
m
o
l
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
)
0.00 0.10 0.15
3-OH-BaP (µM) 4’-OH-CB112 (µM)
–0.75 –0.50 –0.25 0.00 0.25 0.50 0.75 1.00
3
2
1
K
m
/ V
m
a
x
0
0.25 µM
0.5 µM
1.0 µM
Figure 9. Effect of 4´-OH-CB112 on the kinetics of sulfotransferase with 3-OH-BaP in HL cytosol.
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Table 4. Apparent kinetic constants for 3-OH-BaP
sulfotransferase activity in HL cytosol in the pres-
ence and absence of 4´-OH-CB112 (B5).
B5 (µM) Km (µM) Vmax (pmol/min/mg protein)
0 0.045 ± 0.02 A 69.1 ± 8.0 B
0.25 0.043 ± 0.02 A 56.3 ± 6.0 B
0.5 0.045 ± 0.01 A 41.2 ± 3.3 C
1.0 0.066 ± 0.02 A 33.3 ± 3.2 D
Values for liver cytosol are mean ± SD (n = 3), except for
studies with 0.25 µM B5, where two livers were used.
Different letters indicate values that are signiﬁcantly differ-
ent from each other (p < 0.05).inhibitory potency of the OH-PCBs suggested
the possibility that the OH-PCBs competed
with the 3-OH-BaP for an inhibitory site of
the SULT1A1 protein. Gamage et al. (2003)
reported that SULT1A1*2 could accommo-
date two molecules of the xenobiotic model
substrate p-nitrophenol in the active site. They
proposed that substrate inhibition at high con-
centrations of p-nitrophenol was due to
impeded catalysis when both binding sites were
occupied. The active site of SULT1A1 appears
to be plastic enough to accept a wide range of
hydrophobic phenolic compounds (Gamage
et al. 2003) and may be able to accommodate
two molecules of 3-OH-BaP, leading to sub-
strate inhibition, or one molecule of 3-OH-
BaP and one molecule of OH-PCB, resulting
in the OH-PCB inhibiting 3-OH-BaP sul-
fonation. The kinetic studies with 4´-OH-
CB112 (B5) showed that the mechanism of
inhibition was noncompetitive. This result
could ﬁt the scenario for inhibition discussed
above but does not suggest direct competition
of the OH-PCB for binding to the active site
in an orientation that favors sulfonation.
Whatever the mechanism of inhibition, the
loss in inhibitory potency of OH-PCB when
assays were conducted with 1.0 µM 3-OH-
BaP suggested that the enzyme favored binding
of 3-OH-BaP over binding of OH-PCB, and
this was especially true for type C OH-PCBs,
which showed a greater loss in potency than
did the type B compounds. These findings
suggest that OH-PCBs are likely to be poor
substrates for sulfonation, but this has not been
studied in human liver.
We could not discern any other clear
relationship of inhibitory potency with struc-
tural features or with physicochemical proper-
ties of the OH-PCBs in this relatively small
series of compounds, with cytosol or the two
expressed SULT1A1 enzymes. The small size
of the series of compounds studied and the
lack of ready availability of a systematic series
of 4-OH-PCBs prevent further analysis of
structure–potency relationships at this time.
Of the other expressed enzymes studied,
only SULT1E1 exhibited potent inhibition by
the 4-hydroxylated PCBs. The structure–
inhibitory potency requirement for SULT1E1
was very different from that for HL cytosol,
SULT1A1*1, or 1A1*2, where type B com-
pounds were more potent inhibitors than were
type C OH-PCBs. With SULT1E1, OH-
PCBs with no or one ortho-substituted chlorine
were more potent as inhibitors of 3-OH-BaP
sulfonation than were those with two ortho-
substituted chlorine atoms. Substituted
biphenyls with less than one ortho substituent
preferentially adopt coplanar conformation of
the two phenyl rings, whereas those with two
or more ortho substituent atoms take on non-
coplanar conformations. We found a sig-
niﬁcant linear correlation between inhibitory
potency and calculated solution dihedral angles
(Figure 8, Table 3). Similarly, Kester et al.
(2000) found that the best OH-PCB
inhibitors of estrogen sulfonation (IC50 values
< 5 nM) did not have chlorine substituents at
the 2- or the 6-position. Shevtsov et al. (2003)
later showed that 4,4´-di-OH-CB80 (4,4´-di-
OH-3,3´,5,5´-tetrachlorobiphenyl) did not
bind the SULT1E1 in a planar conformation,
but rather with a 30° twist between the phenyl
rings. We found that the four OH-PCBs with
solution dihedral angles of 38° were more
potent inhibitors than were those with larger
dihedral angles. Although it is possible that
interaction with the protein could alter the
conformation of the OH-PCBs, resulting in a
different dihedral angle for the enzyme-bound
OH-PCB, our results show that lack of ortho
substituents is associated with higher inhibitory
potency for a xenobiotic SULT1E1 substrate,
3-OH-BaP.
SULT1A3 metabolized 3-OH-BaP with a
very high Vmax, although its preferred sub-
strates are reported to be catecholamines and
other monocyclic phenols containing hydro-
gen bond donors (Dajani et al. 1998).
Interestingly, 50 µM OH-PCBs caused little
or no inhibition of this enzyme, thereby show-
ing that the inhibitory interaction was enzyme
selective. SULT1B1, the thyroid hormone
sulfotransferase, catalyzed the sulfonation of
3-OH-BaP; however, OH-PCBs that were
potent inhibitors of SULT1A1 were only
weak inhibitors of the SULT1B1-catalyzed
reaction. In contrast to results with the other
enzymes, compound A1 (6´-OH-CB35) was a
fairly potent inhibitor of SULT1B1 (Table 3).
Previously, ortho-, meta-, and para-hydroxy-
lated PCBs were found to inhibit thyroid hor-
mone sulfonation (Schuur et al. 1998). The
meta-hydroxylated PCB, 3-OH-2,3´,4,4´,5-
pentachlorobiphenyl (3-OH-CB118), was the
most potent inhibitor of thyroid hormone
sulfonation in male rat liver cytosol, followed
by two para-hydroxylated PCBs. The ortho-
hydroxylated PCB had the lowest potency
among the four OH-PCBs studied. However,
with 3-OH-BaP as substrate, the ortho-
OH-PCB, 6´-OH-CB35, was a more potent
inhibitor than were those with para-OH
groups, which suggested that the inhibitory
interaction with SULT1B1 was substrate
dependent.
Because several OH-PCBs have been
detected in human blood and are presumably
also present in liver and other tissues, it is
important to understand their biologic activi-
ties. Some OH-PCBs interact with compo-
nents of thyroid hormone and estrogen
hormone systems (Kester et al. 2000; Klasson-
Wehler et al. 1993; Schuur et al. 1998; Sinjari
and Darnerud 1998). Our finding that
OH-PCBs inhibited the sulfonation of 3-OH-
BaP in HL suggests another aspect of the
toxicology of OH-PCBs. The interaction with
phenol sulfotransferase may be of toxicologic
importance because sulfonation is a major
pathway of xenobiotic biotransformation
(Glatt 2002). Sulfonation is particularly
important at low concentrations of hydroxy-
lated xenobiotics, such as may be encountered
from environmental exposure to pollutants
that require CYP-dependent biotransforma-
tion to introduce a hydroxyl group before
their elimination. Formation of sulfate conju-
gates of phenolic xenobiotics usually decreases
their toxicity, so inhibition of this pathway
may lead to prolonged exposure to the parent
compound, a shift to an alternative phase II
conjugation pathway, glucuronidation, or to
further CYP-dependent metabolism. Both
3-OH-BaP and BaP-3-glucuronide bind to
hemoglobin (Sugihara and James 2003), a
potentially toxic interaction. Further CYP-
dependent biotransformation of 3-OH-BaP
may lead to more toxic metabolites such as
3-OH-BaP-7,8-dihydrodiol-9,10-oxide (Glatt
et al. 1987; Ribeiro et al. 1986). On the other
hand, xenobiotics that are activated by sulfo-
nation, such as 2-hydroxyamino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (Ozawa et al.
1998), may be rendered less toxic in the pres-
ence of inhibitors of sulfonation.
Our ﬁndings may be placed in the context
of the structures of OH-PCBs that have been
reported in human blood. All OH-PCB
metabolites identified in blood have the
hydroxy group in a para- or meta-position,
with chlorine atoms on vicinal carbon atoms
(Hovander et al. 2002; Sandau et al. 2000,
2002; Sjodin et al. 2000). The para-OH-PCBs
found in blood are likely to fall into the type C
OH-PCBs examined in this study. Although
these were generally less potent as inhibitors of
SULT1A1 than the type B OH-PCBs, it is
possible that the concentrations of these
OH-PCBs may reach inhibitory levels in tis-
sues of highly exposed people or animals.
Sjodin et al. (2000) reported total measured
OH-PCB concentrations of up to 6 µM in
blood lipids, whereas Sandau et al. (2000)
reported whole blood concentrations up to
30 nM. Tissue concentrations have not been
reported but they may be higher than blood
levels. Type B OH-PCBs with the 3-chloro-
4-hydroxy substitution pattern do not appear
to be persistent in blood; however, of the
209 PCB congeners, 19 have a 3-chloro substi-
tution in one of the phenyl rings, which can be
biotransformed to type B OH-PCBs. If type B
OH-PCBs are formed in people, their high
potency as inhibitors of 3-OH-BaP sulfonation
may cause increased toxicity in people who are
coexposed to PAH and PCBs.
Conclusion
We found that several OH-PCBs, especially
those with a 3-chloro-4-hydroxy substitution
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pattern in the phenolic ring, inhibited the
sulfonation of 3-OH-BaP in cytosol and with
SULT1A1 at submicromolar concentrations.
Some OH-PCBs with no or one ortho chlorine
were potent inhibitors of 3-OH-BaP sulfo-
nation with SULT1E1. SULT1B1- and
SULT1A3-catalyzed sulfonation of 3-OH-BaP
was less sensitive to inhibition by OH-PCBs.
The inhibitory interaction of OH-PCBs with
SULT1A1 and SULT1E1 may have conse-
quences for the biotransformation and toxicity
of phenolic xenobiotics.
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